HUE064252T2 - Antigénkötõ fehérjék töltött mélységi szûrése - Google Patents

Antigénkötõ fehérjék töltött mélységi szûrése

Info

Publication number
HUE064252T2
HUE064252T2 HUE16757780A HUE16757780A HUE064252T2 HU E064252 T2 HUE064252 T2 HU E064252T2 HU E16757780 A HUE16757780 A HU E16757780A HU E16757780 A HUE16757780 A HU E16757780A HU E064252 T2 HUE064252 T2 HU E064252T2
Authority
HU
Hungary
Prior art keywords
antigen
binding proteins
depth filtration
charged depth
charged
Prior art date
Application number
HUE16757780A
Other languages
English (en)
Inventor
Hai Hoang
Rafael Gonzalez
Junfen Ma
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56802689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE064252(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HUE064252T2 publication Critical patent/HUE064252T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44791—Microapparatus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Water Supply & Treatment (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE16757780A 2015-08-13 2016-08-12 Antigénkötõ fehérjék töltött mélységi szûrése HUE064252T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562204831P 2015-08-13 2015-08-13

Publications (1)

Publication Number Publication Date
HUE064252T2 true HUE064252T2 (hu) 2024-02-28

Family

ID=56802689

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16757780A HUE064252T2 (hu) 2015-08-13 2016-08-12 Antigénkötõ fehérjék töltött mélységi szûrése

Country Status (15)

Country Link
US (2) US11098079B2 (hu)
EP (2) EP3334747B1 (hu)
JP (1) JP6889149B2 (hu)
DK (1) DK3334747T3 (hu)
ES (1) ES2964640T3 (hu)
FI (1) FI3334747T3 (hu)
HR (1) HRP20231544T1 (hu)
HU (1) HUE064252T2 (hu)
LT (1) LT3334747T (hu)
MA (1) MA42613A (hu)
PL (1) PL3334747T3 (hu)
PT (1) PT3334747T (hu)
SG (1) SG10202101105XA (hu)
SI (1) SI3334747T1 (hu)
WO (1) WO2017027861A1 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CN107973487B (zh) * 2017-11-14 2021-03-02 东华大学 一种染整废水层级处理工艺及装置
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP2023510382A (ja) * 2020-01-15 2023-03-13 エフ． ホフマン－ラ ロシュ アーゲー 組換えタンパク質製造プロセスから不純物を減少させる方法
CN111410688A (zh) * 2020-03-13 2020-07-14 苏州智享众创孵化管理有限公司 一种提高双特异性抗体纯度的分离纯化方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5237054A (en) 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
CA2195557C (en) 1994-08-12 2006-10-17 Shui-On Leung Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
AUPQ599700A0 (en) 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
CN1970077A (zh) 2001-05-11 2007-05-30 安姆根有限公司 与tall－1结合的肽和相关分子
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
EP1425389B1 (en) 2001-08-23 2011-11-02 Genmab A/S Human antibodies specific for interleukin 15 (il-15)
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
NZ605429A (en) 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
CA2502552C (en) 2002-10-17 2019-02-12 Genmab A/S Human monoclonal antibodies against cd20
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
EP2272864A3 (en) 2002-12-20 2011-02-16 Amgen Inc. Binding agents which inhibit myostatin
SI2335725T1 (sl) 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
DK1648509T3 (da) 2003-07-15 2013-01-07 Amgen Inc Humane anti-NGF-neutraliserende antistoffer som selektive NGF-pathway-inhibitorer
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
CA2543982C (en) 2003-11-07 2013-01-08 Immunex Corporation Antibodies that bind interleukin-4 receptor
JPWO2005063291A1 (ja) 2003-12-25 2007-07-19 麒麟麦酒株式会社 抗体を含有する安定な水性医薬製剤
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
EP1934242B1 (en) 2005-09-15 2018-11-14 Wyeth LLC Protein floculation using salts
US20080132688A1 (en) * 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
WO2008051448A2 (en) 2006-10-19 2008-05-02 Tolerx, Inc. Methods and compositions for efficient removal of protein a from binding molecule preparations
KR101643514B1 (ko) 2007-07-09 2016-07-27 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
DE102008037678A1 (de) * 2008-08-14 2010-02-25 Sartorius Stedim Biotech Gmbh Tiefenfilterschicht mit anorganischem Schichtdoppelhydroxid
SG10201702922VA (en) 2008-10-20 2017-06-29 Abbvie Inc Isolation and purification of antibodies using protein a affinity chromatography
ES2864956T3 (es) * 2009-04-30 2021-10-14 Ablynx Nv Procedimiento para la producción de anticuerpos de dominio
US20120208986A1 (en) 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
CN104744560A (zh) 2009-10-20 2015-07-01 Abbvie公司 使用蛋白a亲和色谱法分离和纯化抗-il-13抗体
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
US20120006751A1 (en) * 2010-05-07 2012-01-12 Millipore Corporation Enhanced Clarification Media
KR20130086540A (ko) 2010-05-18 2013-08-02 아비에 인코포레이티드 단백질 정제 장치 및 방법
WO2012051147A1 (en) * 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
CN103168046A (zh) 2010-10-20 2013-06-19 米迪缪尼有限公司 用于加工包涵体的方法
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
EP3722304A1 (en) 2011-07-08 2020-10-14 EMD Millipore Corporation Improved depth filters for disposable biotechnological processes
FR2977893B1 (fr) 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
DK2739641T4 (da) 2011-08-02 2020-06-15 Baxalta GmbH Systemer og fremgangsmåder til at øge proteinudbytte fra rekombinante fremstillingsfremgangsmåder
US9096648B2 (en) * 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
CN104125963B (zh) 2011-12-22 2018-08-17 弗·哈夫曼-拉罗切有限公司 使用离子交换膜层析改进下游蛋白质纯化步骤的方法
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
TW201348247A (zh) * 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
ES2710314T3 (es) 2012-12-20 2019-04-24 Medimmune Llc Métodos de producción de inmunoconjugados
WO2014196926A1 (en) 2013-06-04 2014-12-11 Agency For Science, Technology And Research Protein purification process
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
GB201318840D0 (en) 2013-10-24 2013-12-11 Univ Leeds Method and device for protein preparation
WO2015070068A1 (en) * 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of antibodies
KR20160118369A (ko) 2014-02-27 2016-10-11 에이전시 포 사이언스, 테크놀로지 앤드 리서치 항체 정제 프로세스
US20170191101A1 (en) 2014-03-17 2017-07-06 Regeneron Pharmaceuticals, Inc. Clarification of mammalian cell culture
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
WO2016106291A1 (en) 2014-12-22 2016-06-30 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins

Also Published As

Publication number Publication date
HRP20231544T1 (hr) 2024-03-15
SI3334747T1 (sl) 2024-02-29
JP6889149B2 (ja) 2021-06-18
EP3334747B1 (en) 2023-09-27
US20210363180A1 (en) 2021-11-25
PL3334747T3 (pl) 2024-04-02
SG10202101105XA (en) 2021-03-30
WO2017027861A1 (en) 2017-02-16
DK3334747T3 (da) 2023-12-11
EP3334747A1 (en) 2018-06-20
US11098079B2 (en) 2021-08-24
PT3334747T (pt) 2023-12-12
EP4209499A1 (en) 2023-07-12
JP2018526357A (ja) 2018-09-13
ES2964640T3 (es) 2024-04-08
MA42613A (fr) 2018-06-20
LT3334747T (lt) 2023-12-27
US20180230180A1 (en) 2018-08-16
FI3334747T3 (fi) 2023-11-30

Similar Documents

Publication Publication Date Title
IL285366A (en) Multi-specific antigen-binding proteins
HK1253235A1 (zh) 抗tigit抗原結合蛋白及其使用方法
IL263690A (en) Purification of multispecific antibodies
HK1231400A1 (zh) 蛋白質的選擇性還原
IL251125B (en) Methods for the separation of gemcitabine-phosphate diastereoisomers
SG10202101105XA (en) Charged depth filtration of antigen-binding proteins
IL248697A0 (en) Methods for purifying antibodies
ZA201808524B (en) Methods of affecting separation
GB201604627D0 (en) Improved method of FT-IMS
IL272670A (en) Preparation of micro-electrodes
SG10202007893TA (en) Methods of immunotherapy
IL252712A0 (en) Method for protein production
IL248694A0 (en) Nanoencapsulation of antigen binding molecules
HK1223624A1 (zh) 替諾福韋的固體形式
GB201609314D0 (en) Methods of forming compounds
TWM533475U (en) Improved structure of filter
GB201508443D0 (en) Methods of identifying USP-binding compounds